Replicate Design [General Sta­tis­tics]

posted by ratnakar1811 – India, 2008-09-02 16:34 (6495 d 18:21 ago) – Posting: # 2303
Views: 8,893

Dear Labes and forum members,

AS per the draft guideline which mentions that, "All treated subjects should be included in the statistical analysis, with the exception of subjects in a crossover trial who do not complete at least one period receiving each of the test and reference products (or who fail to complete the single period in a parallel group trial)." which i guess, means that in a crossover trial if it is a two period study subject should complete both the periods and in case of replicate study subject should complete at least two periods receiving test and reference at least once can be considered.

Comment!

Ratnakar Jadhav

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
152 visitors (0 registered, 152 guests [including 21 identified bots]).
Forum time: 10:56 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5